IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
20.04
+0.48 (2.45%)
At close: May 29, 2025, 4:00 PM
20.05
+0.01 (0.05%)
After-hours: May 29, 2025, 4:27 PM EDT
IDEAYA Biosciences Revenue
IDEAYA Biosciences had revenue of $7.00M in the twelve months ending March 31, 2025, down -54.85% year-over-year. In the year 2024, IDEAYA Biosciences had annual revenue of $7.00M, down -70.07%.
Revenue (ttm)
$7.00M
Revenue Growth
-54.85%
P/S Ratio
243.44
Revenue / Employee
$53,435
Employees
131
Market Cap
1.76B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
IDYA News
- 15 days ago - Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849 - Seeking Alpha
- 23 days ago - IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 23 days ago - IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors - PRNewsWire
- 4 weeks ago - IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events - PRNewsWire
- 4 weeks ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 6 weeks ago - Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later - Seeking Alpha
- 6 weeks ago - IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma - PRNewsWire
- 7 weeks ago - IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer - PRNewsWire